Business Model Breakdown
How Quantum-Si Inc Makes Money
QSI
Market Cap
$207M
Annual Revenue
$3M
Profit Margin
-4160.1%
Employees
149
The Short Version
Quantum-Si generates revenue primarily by selling its proprietary 'Platinum' and upcoming 'Proteus' digital protein sequencing instruments (hardware) to researchers in academia, biotech, and pharmaceutical companies. Once customers have the instruments, the company makes recurring revenue from the sale of consumable chips and reagents essential for running experiments, similar to a 'razor-and-blade' model. This model aims to drive high-margin, sticky revenue from ongoing consumable sales after the initial hardware placement.
Where the Revenue Comes From
Instrument sales (Platinum, Proteus)
Consumables sales (chips, reagents)
Who buys: Academic research institutions, biotechnology companies, pharmaceutical companies, and potentially clinical diagnostic labs in the future.
Why It Works (Competitive Advantages)
- ✔Proprietary single-molecule digital protein sequencing technology (Proteus and Platinum platforms)
- ✔Strong intellectual property portfolio in a novel field
- ✔Founder Jonathan Rothberg's track record of disruptive innovation in life sciences
Economic Moat: Narrow (Intangible Assets/IP (proprietary technology and patents for digital protein sequencing), Switching Costs (potential for high switching costs once instruments are integrated into lab workflows))
What Our Analysis Says
DVR Score as of May 3, 2026
Quantum-Si (QSI) remains a high-risk, high-reward speculation. The successful sequencing demonstration on integrated Proteus instruments is a significant positive, validating the technological promise of their next-generation platform for the multi-billion-dollar proteomics market. This strengthens the long-term vision for market leadership. However, the financial picture has materially weakened, with FY2025 revenue declining 20.3% YoY and Q1 2026 consensus projecting a sharp 64.49% YoY drop. Significant cash burn persists, and net losses are substantial. An analyst downgrade of the price target reflects the challenging commercialization path and the 'transition year' outlook. While the technological execution on Proteus is encouraging, the immediate financial headwinds and prolonged path to profitability have increased the near-term risk profile, leading to a score adjustment. Sustained Proteus adoption and clearer profitability trajectory are critical for re-rating.